Published May 11, 2010 | Version Published + Supplemental Material
Journal Article Open

Genetic control of mammalian T-cell proliferation with synthetic RNA regulatory systems

  • 1. ROR icon California Institute of Technology
  • 2. ROR icon Stanford University

Abstract

RNA molecules perform diverse regulatory functions in natural biological systems, and numerous synthetic RNA-based control devices that integrate sensing and gene-regulatory functions have been demonstrated, predominantly in bacteria and yeast. Despite potential advantages of RNA-based genetic control strategies in clinical applications, there has been limited success in extending engineered RNA devices to mammalian gene-expression control and no example of their application to functional response regulation in mammalian systems. Here we describe a synthetic RNA-based regulatory system and its application in advancing cellular therapies by linking rationally designed, drug-responsive, ribozyme-based regulatory devices to growth cytokine targets to control mouse and primary human T-cell proliferation. We further demonstrate the ability of our synthetic controllers to effectively modulate T-cell growth rate in response to drug input in vivo. Our RNA-based regulatory system exhibits unique properties critical for translation to therapeutic applications, including adaptability to diverse ligand inputs and regulatory targets, tunable regulatory stringency, and rapid response to input availability. By providing tight gene-expression control with customizable ligand inputs, RNA-based regulatory systems can greatly improve cellular therapies and advance broad applications in health and medicine.

Additional Information

© 2010 by the National Academy of Sciences. Edited by Mark E. Davis, California Institute of Technology, Pasadena, CA, and approved March 30, 2010 (received for review February 17, 2010). Published online before print April 26, 2010. This Direct Submission article had a prearranged editor. We thank members of the Smolke Lab, Y.A. Chen, and D. Endy, for critical reading of the manuscript; M.N. Win for contributing expertise on ribozyme switch design; and B. Aguilar, C. Bautista, C. Brown, L. Brown, W. Chang, R. Diamond, A. Hamlett, M. Hunter, D. Perez, G. Raval, J. Wagner, W. Wong, and C. Wright for technical assistance. This work was supported by the City of Hope's National Cancer Institute-Cancer Center Support Grant, the National Science Foundation (fellowship to Y.Y.C.), and the Alfred P. Sloan Foundation (fellowship to C.D.S.). Author contributions: Y.Y.C., M.C.J., and C.D.S. designed research; Y.Y.C. performed research; Y.Y.C., M.C.J., and C.D.S. analyzed data; and Y.Y.C., M.C.J., and C.D.S. wrote the paper.

Attached Files

Published - Chen2010p10145P_Natl_Acad_Sci_Usa.pdf

Supplemental Material - pnas.1001721107_SI.pdf

Files

Chen2010p10145P_Natl_Acad_Sci_Usa.pdf

Files (2.4 MB)

Name Size
md5:ce6d8ddf319902a778341e84069c0d22
682.8 kB Preview Download
md5:614d4f6c9db34ce7843cdf56bf740f17
1.7 MB Preview Download

Additional details

Identifiers

PMCID
PMC2889348
Eprint ID
18630
Resolver ID
CaltechAUTHORS:20100610-082526664

Funding

City of Hope's National Cancer Institute-Cancer Center
NSF
Alfred P. Sloan Foundation

Dates

Created
2010-06-17
Created from EPrint's datestamp field
Updated
2021-11-08
Created from EPrint's last_modified field